ClouDr Group has a Cash Ratio of 0.39. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for ClouDr Group's Cash Ratio or its related term are showing as below:
HKSE:09955'
s Cash Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.35 Max: 0.82
Current: 0.39
During the past 5 years, ClouDr Group's highest Cash Ratio was 0.82. The lowest was 0.05. And the median was 0.35.
HKSE:09955's Cash Ratio is ranked better than 64.22% of 109
companies
in the Medical Distribution industry
Industry Median: 0.19
vs HKSE:09955: 0.39
ClouDr Group Cash Ratio Historical Data
The historical data trend for ClouDr Group's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ClouDr Group's Cash Ratio
For the Medical Distribution subindustry, ClouDr Group's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClouDr Group's Cash Ratio Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, ClouDr Group's Cash Ratio distribution charts can be found below:
* The bar in red indicates where ClouDr Group's Cash Ratio falls into.
ClouDr Group Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
ClouDr Group's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClouDr Group (HKSE:09955) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
ClouDr Group Cash Ratio Related Terms
Thank you for viewing the detailed overview of ClouDr Group's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. Its segments include in-hospital solutions, pharmacy solutions, and individual chronic condition management solutions. The company's in-hospital solution consists of sales of medical devices, consumables and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies. It generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09955 has been successfully added to your 